glp-1 and parkinson's disease A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes obesity, including cardiovascular and neurodegenerative disorders BQURA | R&D News -

T.GhimJ.KwonY.et al

Tirzepatide's SURMOUNT-5 head-to-head vs semaglutide (2025): Zepbound demonstrated 47% greater relative weight loss vs Wegovy in a direct Phase 3b comparison the most commercially significant clinical trial result in the obesity market, directly challenging Novo Nordisk's market leadership

Similarly, pressing the pen too firmly against the skin can compress the tissue and bring the needle closer to the muscle, while pressing too lightly might result in an incomplete injection or a grazing sensation on the skin surface

commercially available in creams and serums at concentrations of 1-3% Subcutaneous injection : Research doses typically 100-200 mcg administered locally Iontophoresis : Electrical delivery through skin has been studied for enhanced penetration Microneedling combination : Topical application combined with microneedling for deeper delivery The topical availability of GHK-Cu makes it significantly more accessible than BPC-157 for surface-level applications

A: Reaching your goal weight is fantastic congrats in advance